MSMartina Schifferer

Martina Schifferer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martina Schifferer has a total of 344 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic progressive demyelination induces a microglial state with lysosomal dysfunction

    by Stefan A. Berghoff, Lena Spieth, Simona Vitale, Lennart Schlaphoff, Martin Zirngibl, Niklas Junker, Alan-Charles Dean, Lu Liu, Alkmini Damkou, Stefan Roth, et al.

    Dysfunctional immune responses impair remyelination and contribute to neurodegeneration. While immune and metabolic responses to acute myelin injury are well characterized, myeloid cell adaptations to chronic myelin damage remain poorly understood. Here we performed a comparative analysis of genetic and toxic mouse models of acute and chronic demyelination, which identified a distinct microglial state associated with chronic demyelination, characterized by sustained pro-inflammatory activation, lysosomal lipid sequestration and reduced lipid droplet formation. Transcriptomics profiling further revealed a metabolic program marked by upregulated cholesterol synthesis and diminished sterol efflux. Treatment with a desmosterol mimetic possessing 24-dehydrocholesterol reductase inhibitor activity reversed this microglial state, attenuated pro-inflammatory signaling (including C-C Motif Chemokine Ligand 4 expression), reduced myelin damage and improved motor performance in a mouse model of leukodystrophy. Our findings uncover a pro-inflammatory microglial state characterized by lysosomal dysfunction and increased myelin reactivity, highlighting a novel therapeutic target for chronic demyelinating disorders.


  • Open Access

    Ubiquitin ligase RNF126 exerts functions in lysosomal damage response and lysosomal homeostasis maintenance

    by Sophie Levantovsky, Bojana Kravić, Lizhen Cheng, Lukas Brecht, Hanna Tolle, Pinki Gahlot, Georg Kislinger, Kimberly Cramer, Regina Feederle, Benedikt Wefers, et al.

    The response to lysosomal membrane permeabilization involves extensive ubiquitylation at the lysosome; however, the ubiquitin ligases identified so far cannot account for the complexity of the response. Using extensive spatial proteomics, we identified RNF126 as a new ligase that is robustly recruited to lysosomes in response to a range of different damage triggers across distinct cell types. Recruitment is mediated independent of BAG6 via an arginine-rich stretch in the low-complexity region of RNF126 to mostly unacidified lysosomes in the perinuclear region. Ubiquitin remnant mass spectrometry identified several damage-induced RNF126 substrates, among them known lysosomal damage response components and potential new factors that might drive regeneration from lysosomal damage. Consistently, RNF126 deletion resulted in persistent lysosomal swelling. In addition, we uncovered a constitutive role of RNF126 in lysosomal homeostasis maintenance. Hence, our findings identified the ubiquitin ligase RNF126 as novel lysosomal health regulating factor with functions in homeostasis and stress conditions.

  • Open Access

    Author Correction: T cell-mediated microglial activation triggers myelin pathology in a mouse model of amyloidosis

    by Shreeya Kedia, Hao Ji, Ruoqing Feng, Peter Androvic, Lena Spieth, Lu Liu, Jonas Franz, Hanna Zdiarstek, Katrin Perez Anderson, Cem Kaboglu, et al.

  • Open Access

    A reproducible three-dimensional model of human brain tissue to investigate physiological and disease-associated microglia phenotypes

    by Julien Klimmt, Carolina Cardoso Gonçalves, Jessica Valentina Montgomery, Stephan A. Müller, Merle Bublitz, Severin Filser, Lars Paeger, Brigitte Nuscher, Angelika Dannert, Sigrun Roeber, et al.

    Stem-cell-based in vitro models offer promising potential to elucidate human brain cell functions and interactions, but limitations in reproducibility, maturation and cell-type diversity persist. Especially, prolonged incorporation of mature microglia and studies of neuroinflammation have proven challenging. Here, we developed a human induced pluripotent stem cell-based three-dimensional cortical brain tissue model (3BTM) containing neurons, astrocytes and microglia with high reproducibility, maturity and viability. 3BTMs show morphological, functional and proteomic maturation of all cell types, leading to high similarity to their in vivo counterparts. Incorporated microglia survive for over 6 months and display mature morphology, functions and gene expression. Importantly, when engineered to model Alzheimer’s disease pathology, 3BTMs recapitulate key disease hallmarks, including amyloid deposition, increased phospho-tau levels and neuroinflammation, with microglia shifting their transcriptional landscape to disease-relevant signatures. Treatment of Alzheimer’s disease 3BTMs with anti-Aβ immunotherapy cleared deposits and largely reversed disease signatures in glia. Together, our microglia-containing model provides a platform for studying physiological and pathological states of human brain tissue.


  • Open Access

    Endothelial cannabinoid CB1 receptor deficiency reduces shear stress-induced arterial inflammation and lipid uptake

    by Bingni Chen, Aishvaryaa Prabhu, Guo Li, Anna Kaltenbach, Yong Wang, George Shakir, Lucia Natarelli, Remco Megens, Yvonne Jansen, Srishti Ramanathan, et al.

    Peripheral cannabinoid CB1 receptor antagonists that lack central nervous system effects are emerging as promising therapies for metabolic disease, yet the role of endothelial CB1 signaling in atherosclerosis remains unclear. Here, we show that endothelial CB1 is expressed in human atherosclerotic plaques, is induced by oscillatory shear stress in atheroprone flow regions, and promotes vascular inflammation, permeability and lipid uptake. Endothelial-specific Cnr1 deletion or peripheral CB1 antagonism in mice attenuates atherosclerosis, reduces endothelial caveolae–dependent low-density lipoprotein uptake by downregulating caveolin-1 and ALK1 expression, and improves metabolic parameters in brown and white adipose tissue and the liver. The anti-atherogenic and metabolic effects are more pronounced in females, which is possibly linked to estrogen signaling. These findings identify endothelial CB1 as a proatherogenic, sex-biased regulator of vascular lipid transport and plaque development and associated metabolic dysfunction.


  • A human iPSC model of tauopathies engineered for 4R tau isoform expression endogenously develops late-stage neuronal tau pathology

    by Angelika Dannert, Nathalie Schulz, Julien Klimmt, Lea Knez, Bernhard Groschup, Carolina Cardoso Gonçalves, Caterina Carraro, Martina Schifferer, Matthias Brendel, Dominik Paquet

    Tauopathies, such as Alzheimer’s disease and frontotemporal dementia, are common neurodegenerative diseases characterized by misfolding, hyperphosphorylation, and aggregation of tau. Molecular mechanisms underlying tauopathies are still poorly understood, which is in part due to a lack of human models autonomously developing major disease hallmarks. The formation of late-stage disease phenotypes may require adult tau isoform expression, which contributes to tau pathogenesis but is challenging to replicate in human stem cell–derived systems, thus impeding research on underlying mechanisms and drug development. Here, we show that induction of adult human brain–like 4R tau isoform expression enables cell-intrinsic formation of late-stage tauopathy hallmarks in induced pluripotent stem cell–derived neurons engineered to contain synergistic tau mutations without exogenous sources of tau pathology. Neurons accumulated seeding-competent and hyperphosphorylated tau in tangle-like structures. Furthermore, exclusive expression of mutant 4R in the absence of the 3R tau isoform disproportionately intensified pathology, resulting in abundant tau misfolding and aggregation. Last, we provide proof of principle that our model can be translationally applied both to test chemical disease modulators and evaluate human tau PET tracers. Collectively, our model corroborates the central role of 4R tau isoform expression for pathogenesis in human neurons and enables investigations to elucidate mechanisms underlying human tauopathy formation. Moreover, it may serve as a platform supporting urgently needed development of disease-modifying drugs.


  • Open Access

    VMAT2 dysfunction impairs vesicular dopamine uptake, driving its oxidation and α-synuclein pathology in DJ-1–linked Parkinson’s neurons

    by Leonie M. Heger, Francesco Gubinelli, Andreas J. Huber, Aida Cardona-Alberich, Matteo Rovere, Ulf Matti, Stephan A. Müller, Sankarshana R. Nagaraja, Lena Jaschkowitz, Martina Schifferer, et al.

    Parkinson’s disease (PD) is characterized by α-synuclein accumulation and dopaminergic neuron degeneration, with dopamine (DA) oxidation emerging as a key pathological driver. However, the mechanisms underlying this neurotoxic process remain unclear. Using PD patient-derived and CRISPR-engineered induced pluripotent stem cell midbrain dopaminergic neurons lacking DJ-1, we identified defective sequestration of cytosolic DA into synaptic vesicles, which culminated in DA oxidation and α-synuclein pathology. In-depth proteomics, state-of-the-art imaging, and ultrasensitive DA probes uncovered that decreased vesicular monoamine transporter 2 (VMAT2) protein and function impaired vesicular DA uptake, resulting in reduced vesicle availability and abnormal vesicle morphology. Furthermore, VMAT2 activity and vesicle endocytosis are processes dependent on adenosine 5′-triphosphate (ATP), which is notably reduced in DJ-1–deficient dopaminergic neurons. ATP supplementation restored vesicular function and alleviated DA-related pathologies in mutant dopaminergic neurons. This study reveals an ATP-sensitive mechanism that regulates DA homeostasis through VMAT2 and vesicle dynamics in midbrain dopaminergic neurons, highlighting enhanced DA sequestration as a promising therapeutic strategy for PD.


  • Open Access

    A reproducible human brain tissue model to study physiological and disease-associated microglia phenotypes

    by Julien Klimmt, Carolina Cardoso Gonçalves, Jessica Valentina Montgomery, Stephan A. Müller, Merle Bublitz, Severin Filser, Lars Paeger, Brigitte Nuscher, Angelika Dannert, Sigrun Roeber, et al.

    Stem-cell-based in vitro models offer promising potential to elucidate human brain cell functions and interactions under physiological and pathological conditions. However, harnessing this potential is impaired by low reproducibility, maturity, or cell-type diversity of existing models. Especially, prolonged incorporation of mature microglia and studies of neuroinflammation have proven challenging. Here, we developed a 3D cortical brain tissue model (3BTM) containing neurons, astrocytes, and microglia with high reproducibility, maturity, and viability. 3BTMs show morphological, functional, and proteomic maturation of all cell types, leading to high similarity to their in vivo counterparts. Incorporated microglia survive for over 6 months and display mature morphology, functions, and gene expression. Importantly, when engineered to model Alzheimer’s disease pathology, 3BTMs recapitulate key disease hallmarks including amyloid deposition, increased phospho-Tau levels, and neuroinflammation, with microglia shifting their transcriptional landscape to disease-relevant signatures. Together, our model offers unprecedented possibilities for studying physiological and pathological states of human brain tissue and translational applications.

  • Open Access

    The stroke risk gene Foxf2 maintains brain endothelial cell function via Tie2 signaling

    by Katalin Todorov-Völgyi, Judit González-Gallego, Stephan A. Müller, Mihail Ivilinov Todorov, Fatma Burcu Seker, Simon Frerich, Filippo M. Cernilogar, Luise Schröger, Rainer Malik, Jiayu Cao, et al.

    Cerebral small vessel disease (SVD) is a common chronic cerebrovascular disorder with poorly understood pathomechanisms. Genetic studies have identified FOXF2 as a major risk gene for both SVD and stroke. FOXF2 encodes a transcription factor primarily expressed in brain pericytes and endothelial cells (ECs); however, its mechanistic role in cerebrovascular disease remains unknown. Here we show that Foxf2 maintains EC function through Tie2 signaling. RNA and chromatin sequencing identified FOXF2 as a transcriptional activator of Tie2 and other endothelial lineage-specific genes. The deletion of EC-specific Foxf2 in adult mice resulted in blood–brain barrier leakage, which worsened after experimental stroke. Proteomic analyses of Foxf2-deficient mouse brain-derived and human-induced pluripotent stem cell-derived ECs that lack FOXF2 revealed a downregulation of multiple proteins involved in Tie2 signaling. Endothelial Foxf2 deficiency impaired functional hyperemia, reduced NO production and increased infarct size through disrupted Tie2 signaling, effects that were rescued by pharmacological activation of Tie2 with AKB-9778. Collectively, our results highlight the critical role of Foxf2-regulated Tie2 signaling in SVD and stroke, suggesting new avenues for therapeutic interventions.


  • Open Access

    A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions

    by Judit González-Gallego, Katalin Todorov-Völgyi, Stephan A. Müller, Sophie Antesberger, Mihail Ivilinov Todorov, Rainer Malik, Rita Grimalt-Mirada, Carolina Cardoso Gonçalves, Martina Schifferer, Georg Kislinger, et al.

    Blood–brain barrier (BBB) integrity is critical for brain homeostasis, with malfunctions contributing to neurovascular and neurodegenerative disorders. Mechanistic studies on BBB function have been mostly conducted in rodent and in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human induced pluripotent stem (iPS)-cell-derived, microfluidic three-dimensional (3D) BBB model consisting of endothelial cells (ECs), mural cells and astrocytes. Our model expresses typical fate markers, forms a barrier in vessel-like tubes and enables perfusion, including with human blood. Deletion of FOXF2 in ECs, a major risk gene for cerebral small vessel disease, induced key features of BBB dysfunction, including compromised cell junction integrity and enhanced caveolae formation. Proteomic analysis revealed dysregulated endocytosis and cell junction pathways. Disease features phenocopied those seen in mice with EC-specific Foxf2 deficiency. Moreover, lipid-nanoparticle-based treatment with Foxf2 mRNA rescued BBB deficits, demonstrating the potential for drug development.